Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
4 Excellent Remote Headphones of 2024 - 2Joshua Made Last-Second Seat Change That Saved His Life
- 3Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 4California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- 5Overhaul Your Rest: Tips for a Serene Evening
- Well known SUVs With Low Energy Utilization In 2024
- Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
- Pfizer says patient dies after receiving hemophilia drug in trial
- Kremlin: Russian troops conquer Pokrovsk after year of intense combat
- 5 Wellbeing Applications Assist You With remaining Fit
- At least 18 Palestinians killed in latest clashes in Gaza
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- 5 Pizza Fixings That Characterize Your Character
- Finding the Universe of Computer generated Reality: Individual Encounters
